Several actors that regulate the balance between degradation and secretion are altered in AD patients, examples hereof are the increased plasma Atg5 levels and the selective deficiency of PI3P in several brain regions (prefrontal and entorhinal cortex) [48,106]. The gene discussed is ATG5; the disease is Alzheimer disease.